European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The Eu-IGFD is a descriptive, multicenter, observational, prospective, open-ended, non
interventional, post-authorisation surveillance registry. The purpose of this study is to
collect long-term safety information on the use of recombinant DNA-derived human Insulin-like
Growth Factor-1 (rhIGF-I) Increlex® replacement therapy for the treatment of children with
growth failure.